Research programme: psychedelic and empathogenic compounds - Definium Therapeutics/MindShift Compounds
Latest Information Update: 22 Jan 2026
At a glance
- Originator MindShift Compounds
- Class Drug withdrawal therapies; Ergolines; Neuropsychotherapeutics; Phenethylamines; Tryptamines
- Mechanism of Action Serotonin 5-HT2A receptor agonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Mental disorders; Substance-related disorders